Astellas Pharma Inc. (ALPMY)
OTCMKTS
· Delayed Price · Currency is USD
9.56
+0.11 (1.16%)
Jun 26, 2025, 3:53 PM EDT
Astellas Pharma Revenue
In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T JPY with 19.25% growth. Astellas Pharma had revenue of 459.29B in the quarter ending March 31, 2025, with 10.78% growth.
Revenue
1,912.32B JPY
Revenue Growth
+19.25%
P/S Ratio
1.34
Revenue / Employee
140.17M JPY
Employees
13,643
Market Cap
17.16B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,912.32B | 308.65B | 19.25% |
| Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
| Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
| Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
| Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Astellas Pharma News
- 13 days ago - Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan - PRNewsWire
- 14 days ago - Lupin shares in focus after US Court rejects plea in Astellas Patent case - Business Upturn
- 4 weeks ago - Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - PRNewsWire
- 4 weeks ago - Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers - PRNewsWire
- 5 weeks ago - Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Benzinga
- 5 weeks ago - Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio - PRNewsWire
- 2 months ago - Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses - PRNewsWire
- 2 months ago - Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript - Seeking Alpha